ASX Health Stocks: Adherium jumps 12pc on supply deal for AstraZeneca
Health & Biotech
Health & Biotech
Link copied to
The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08%
Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded a contract to supply its Hailie solution for an upcoming US-based clinical study by AstraZeneca.
The sensors and software will be supplied for commencement of the study during FY22, and will generate approximately US$650k in revenue for ADR.
The Hailie Sensor was given a US FDA 510(k) approval earlier this month, allowing the company to market the device in the US to monitor Asthma and Chronic Obstructive Pulmonary Disease (COPD).
The device attaches to a patient’s asthma or medication inhaler to allow caregivers to provide advanced patient monitoring.
The company says the Indian drugs regulatory agency has reviewed and formally recommended the DMX-200 clinical study in COVID-19 patients be approved.
Multiple clinical sites in India have now been initiated by Dimerix, and are ready to begin recruitment in the Phase 3 clinical study of DMX-200.
India’s National Institute of Disaster Management has warned of an imminent third wave of COVID-19 in the country that’s expected to peak around October.
Meanwhile, the DMX-200 is separately being trialled in a Phase3 study for the rare kidney disease, Focal Segmental Glomerulosclerosis (FSGS).
Dimerix secured a marquee $20m share placement backed by key cornerstone investors in August to support this study.
Antisense (ASX:ANP) +7.5%
The company said data from its ATL1102 Phase II trial was presented today at the 26th International Annual Congress of the World Muscle Society.
The data supports the potential for ATL1102 as a prospect for the treatment of both non-ambulant and ambulant patients with DMD (duchenne muscular dystrophy) – an inherited disorder of progressive muscular weakness typically found in boys.
Earlier this week, Antisense also presented ATL1102 proteomics data at the same conference, which showed efficacy in reducing multiple sclerosis (MS) lesions.
That ATL1102 Phase IIa data from the study was also published in the medical journal, Neurology.
The wholesale pharmaceutical distribution company has just appointed a new CEO, Vikesh Ramsunder.
Ramsunder is currently Group CEO of the Clicks Group, a leading healthcare market player in South Africa, a role that he’s held since 2019.
Ramsunder will be replacing current CEO Mark Hooper, who would remain with Sigma until the end of October.
Paradigm has received an Australian ethics approval for the Phase 3 clinical trial of its drug PARA_OA_002, to treat patients with knee osteoarthritis pain.
Paradigm also expects to receive a response from the US FDA before end of this month for its Investigational New Drug (IND) application, to begin the US arm of the study.
In August, Paradigm encountered a setback when the FDA questioned its original IND submission.
The company has submitted a response, and is now waiting for the final approval from the FDA.